Kolon TissueGene, Inc. (KOSDAQ:950160)
South Korea
· Delayed Price · Currency is KRW 41,500
+600 (1.47%)
Jun 27, 2025, 3:30 PM KST
Kolon TissueGene Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 5,149 | 5,073 | 3,706 | 9,456 | 4,003 | 3,556 | Upgrade
| |
Revenue Growth (YoY) | 16.97% | 36.90% | -60.81% | 136.22% | 12.58% | 17.17% | Upgrade
|
Cost of Revenue | 4,607 | 4,528 | 3,340 | 1,811 | 3,611 | 3,230 | Upgrade
|
Gross Profit | 542.11 | 545.13 | 365.92 | 7,645 | 392.15 | 326 | Upgrade
|
Selling, General & Admin | 14,697 | 15,849 | 13,679 | 14,694 | 15,906 | 24,355 | Upgrade
|
Research & Development | 7,923 | 5,612 | 5,635 | 7,123 | 29,890 | 15,724 | Upgrade
|
Other Operating Expenses | 322.57 | 269.39 | 173.93 | 224.81 | 56.02 | 250.31 | Upgrade
|
Operating Expenses | 23,716 | 22,543 | 20,877 | 23,953 | 47,493 | 41,883 | Upgrade
|
Operating Income | -23,174 | -21,998 | -20,511 | -16,308 | -47,101 | -41,557 | Upgrade
|
Interest Expense | -84.48 | -89.85 | -285.82 | -371.18 | -466.46 | -835.26 | Upgrade
|
Interest & Investment Income | 1,022 | 1,040 | 2,221 | 670.49 | 129.69 | 876.57 | Upgrade
|
Currency Exchange Gain (Loss) | 454.4 | 813.15 | 256.82 | 1,512 | 50.89 | -69.97 | Upgrade
|
Other Non Operating Income (Expenses) | -14,160 | -13,661 | 1,351 | 4,676 | 249.99 | -79.74 | Upgrade
|
EBT Excluding Unusual Items | -35,942 | -33,895 | -16,968 | -9,821 | -47,136 | -41,665 | Upgrade
|
Gain (Loss) on Sale of Assets | -0.23 | 1.02 | -3.43 | - | -14.87 | 0.5 | Upgrade
|
Pretax Income | -35,942 | -33,894 | -16,971 | -9,821 | -47,151 | -41,665 | Upgrade
|
Income Tax Expense | -95.84 | -95.47 | 253.15 | 1,316 | 218.27 | 123.68 | Upgrade
|
Net Income | -35,846 | -33,799 | -17,224 | -11,136 | -47,370 | -41,788 | Upgrade
|
Net Income to Common | -35,846 | -33,799 | -17,224 | -11,136 | -47,370 | -41,788 | Upgrade
|
Shares Outstanding (Basic) | 79 | 77 | 72 | 66 | 61 | 61 | Upgrade
|
Shares Outstanding (Diluted) | 79 | 77 | 72 | 66 | 61 | 61 | Upgrade
|
Shares Change (YoY) | 9.92% | 7.32% | 8.18% | 8.25% | 0.29% | -0.06% | Upgrade
|
EPS (Basic) | -452.29 | -439.20 | -240.20 | -168.00 | -773.60 | -684.40 | Upgrade
|
EPS (Diluted) | -452.29 | -439.20 | -240.20 | -168.00 | -773.60 | -684.40 | Upgrade
|
Free Cash Flow | -34,107 | -20,581 | -24,370 | -26,844 | -40,568 | -38,952 | Upgrade
|
Free Cash Flow Per Share | -430.35 | -267.44 | -339.84 | -404.97 | -662.52 | -637.95 | Upgrade
|
Gross Margin | 10.53% | 10.75% | 9.87% | 80.85% | 9.80% | 9.17% | Upgrade
|
Operating Margin | -450.07% | -433.58% | -553.45% | -172.46% | -1176.59% | -1168.69% | Upgrade
|
Profit Margin | -696.19% | -666.19% | -464.76% | -117.77% | -1183.31% | -1175.21% | Upgrade
|
Free Cash Flow Margin | -662.42% | -405.66% | -657.56% | -283.88% | -1013.40% | -1095.44% | Upgrade
|
EBITDA | -22,406 | -21,189 | -19,099 | -14,643 | -45,550 | -39,914 | Upgrade
|
EBITDA Margin | - | - | - | -154.85% | - | - | Upgrade
|
D&A For EBITDA | 767.85 | 808.55 | 1,412 | 1,665 | 1,551 | 1,642 | Upgrade
|
EBIT | -23,174 | -21,998 | -20,511 | -16,308 | -47,101 | -41,557 | Upgrade
|
EBIT Margin | - | - | - | -172.46% | - | - | Upgrade
|
Advertising Expenses | - | 37.32 | 11.48 | 0.5 | 18.66 | 68.88 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.